sirolimus — Topline data
Q3 2026
An ongoing double-blind, placebo-controlled Phase 2 IIT of eRapa in NMIBC has enrolled all 166 patients and is expected to read out in the third quarter of 2026.Source filing
BDRX biotech catalysts & pipeline
BIODEXA PHARMACEUTICALS PLC · Data as of 2026-09-08
Upcoming catalysts
sirolimus — Topline data
H2 2029
The Phase 3 study is expected to take approximately 18 months to recruit all 168 patients and database lock will occur after 75 events which is expected to be in the second half of 2029.Source filing